Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)

Journal of Clinical Oncology

Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J. . Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022; 16(40):s3001.

2022
https://researcherprofiles.org/profile/530203619

Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.